Rates of Screening, Diagnosis, and Treatment of Depression in Patients With Extremity Soft Tissue Sarcomas

ABSTRACT Background Soft tissue sarcomas (STS) are rare malignancies that can be associated with physical and psychological burden. Depression is a common comorbidity in cancer patients; however, mental health screening and treatment patterns in STS remain poorly characterised. This study evaluated national rates of depression screening, diagnosis, and antidepressant use among patients with extremity STS. Methods Using the TriNetX U.S. Collaborative Network, we conducted a retrospective matched cohort study of adults diagnosed with extremity STS between 2007 and 2025. Patients with no cancer history served as controls. Primary outcomes included encounters for depression screening, brief emotional/behavioural assessment, depression‐associated diagnoses, and antidepressant prescriptions. Subgroup analyses compared STS patients receiving chemotherapy and/or radiation therapy versus those who did not. Results After matching, 7295 patients were included per cohort. Compared with controls, patients with extremity STS had significantly lower risks of encounters for depression screening (RR: 0.13, 95% CI: 0.10–0.17) and brief emotional/behavioural assessment (RR: 0.17, 95% CI: 0.13–0.23). In contrast, patients with extremity STS had an increased risk of depression associated diagnoses (RR: 1.99, 95% CI: 1.76–2.24) and antidepressant prescriptions (RR: 1.81, 95% CI: 1.65–1.98). Among STS patients, those receiving chemotherapy and/or radiation therapy had higher risks of depression‐associated diagnoses (RR 1.30, 95% CI 1.10–1.54) and antidepressant use (RR 1.83, 95% CI 1.61–2.09). Conclusion Patients with extremity STS were less likely to undergo depression screening, suggesting under‐recognition of depression despite elevated psychosocial risk. Those receiving chemotherapy and/or radiation therapy demonstrated higher depression‐related diagnoses and antidepressant use. Integrating mental health screening and support throughout sarcoma care may enhance comprehensive patient management.

Authors

Institutions

Publication Details

Journal
Musculoskeletal Care
Published
2026-11-15
DOI
https://doi.org/10.1002/msc.70289
Primary Topic
Cancer survivorship and care
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rates of Screening, Diagnosis, and Treatment of Depression in Patients With Extremity Soft Tissue Sarcomas

Dale Randall Shepard, Zachary D. C. Burke, Jacob G. Scott, Nathan W. Mesko et al.
Musculoskeletal Care
Cancer survivorship and care
article

Rates of Screening, Diagnosis, and Treatment of Depression in Patients With Extremity Soft Tissue Sarcomas

Dale Randall Shepard, Zachary D. C. Burke, Jacob G. Scott, Nathan W. Mesko, Joseph R. Wooley, Lukas M. Nystrom, Brian Benyamini, Eduardo Williams-Medina
article en

Abstract

ABSTRACT Background Soft tissue sarcomas (STS) are rare malignancies that can be associated with physical and psychological burden. Depression is a common comorbidity in cancer patients; however, mental health screening and treatment patterns in STS remain poorly characterised. This study evaluated national rates of depression screening, diagnosis, and antidepressant use among patients with extremity STS. Methods Using the TriNetX U.S. Collaborative Network, we conducted a retrospective matched cohort study of adults diagnosed with extremity STS between 2007 and 2025. Patients with no cancer history served as controls. Primary outcomes included encounters for depression screening, brief emotional/behavioural assessment, depression‐associated diagnoses, and antidepressant prescriptions. Subgroup analyses compared STS patients receiving chemotherapy and/or radiation therapy versus those who did not. Results After matching, 7295 patients were included per cohort. Compared with controls, patients with extremity STS had significantly lower risks of encounters for depression screening (RR: 0.13, 95% CI: 0.10–0.17) and brief emotional/behavioural assessment (RR: 0.17, 95% CI: 0.13–0.23). In contrast, patients with extremity STS had an increased risk of depression associated diagnoses (RR: 1.99, 95% CI: 1.76–2.24) and antidepressant prescriptions (RR: 1.81, 95% CI: 1.65–1.98). Among STS patients, those receiving chemotherapy and/or radiation therapy had higher risks of depression‐associated diagnoses (RR 1.30, 95% CI 1.10–1.54) and antidepressant use (RR 1.83, 95% CI 1.61–2.09). Conclusion Patients with extremity STS were less likely to undergo depression screening, suggesting under‐recognition of depression despite elevated psychosocial risk. Those receiving chemotherapy and/or radiation therapy demonstrated higher depression‐related diagnoses and antidepressant use. Integrating mental health screening and support throughout sarcoma care may enhance comprehensive patient management.

Musculoskeletal CareVol. 24(4)
Cleveland Clinic (US), Cleveland Clinic Lerner College of Medicine (US), Case Western Reserve University (US)
Cancer survivorship and care
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon